FT: Pharma payments to U.S. docs hit $150M

A dozen drugmakers have paid 165,000 U.S. doctors nearly $150 million so far this year, the Financial Times finds; last year's total was $437 million for 262,000 doctors. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.